CT 스캐너 시장, 호라이즌 리포트 : 세계 시장 구조, 예측, 임상 수요, 경쟁 동향 및 AI 수익화 아키텍처(2024-2035년)

Report Overview

This Marketstrat® Horizon report provides an in-depth global analysis of the computed tomography (CT) market and the wider CT ecosystem from 2024A to 2035E. It is written for medical imaging OEM executives, corporate strategy and development teams, service and aftermarket leaders, component suppliers, clinical AI companies, enterprise imaging platforms, investors, provider organizations, and commercial teams with exposure to CT.

The report brings CT systems, installed-base economics, procedure demand, replacement and expansion shipments, realized ASPs, service contracts, X-ray tubes and parts, software upgrades, clinical AI, enterprise AI orchestration, financing, and selected adjacencies into one reconciled decision model.

Most CT market studies stop at scanner shipments, slice counts, or top-line equipment revenue. This report follows value across the full CT lifecycle and asks a harder commercial question: who will control the premium configuration, service relationship, software upgrade path, clinical AI workflow, enterprise platform, and financing structure around the installed scanner?

The analysis was developed through Markintel®, Marketstrat's proprietary research methodology and strategic framework stack. It pairs a bottom-up global market model with analytical cuts by scanner tier, clinical segment, end-use organization, and geography, each reconciled to the same governing totals.

Key Questions Answered

• Where does CT revenue growth come from when mature-market unit demand is largely replacement-driven?
• How quickly does value shift toward spectral, dual-energy, and photon-counting systems, and what does that mean for the installed base?
• How much of the CT opportunity sits in service, tubes, parts, and software upgrades compared with new systems?
• Which CT AI use cases have a credible path to paid, recurring revenue, and which remain embedded in scanner or upgrade economics?
• How do clinical demand drivers and buyer consolidation change product, pricing, and contracting requirements?
• How should vendors approach China, India, and other capacity-expansion markets differently from replacement-led markets?
• Which competitors control the commercial layers that matter most through 2035E?

Market Snapshot

CT is one of the most clinically essential and operationally resilient imaging modalities. It supports emergency medicine, trauma, stroke, oncology, cardiovascular imaging, pulmonary disease, vascular assessment, abdominal diagnosis, interventional procedures, and population screening.

Global CT procedure volume grows from roughly 560 million examinations in 2024A to more than 870 million in 2035E, and the active installed base expands from roughly 98,000 to 152,000 scanners. Those figures do not describe one homogeneous growth cycle.

Mature markets are mostly replacement-led. Their economics turn on fleet age, utilization, premium configuration, service attachment, software upgrades, AI adoption, and enterprise contracting. Lower-density markets remain expansion-led, and converting clinical need into placements there depends on capital availability, public procurement, financing, service coverage, workforce, and realized system pricing.

Systems revenue grows steadily, while service, tubes and parts, software, clinical AI, and orchestration grow the economic value of each installed scanner at a faster rate. The report quantifies this value migration under Base, Bull, and Bear scenarios.

Key Market Trends

• 1. Premium CT is moving beyond slice-count competition. Differentiation now rests on detector architecture, spectral capability, reconstruction, cardiac performance, and the software and service bundle sold with the system. Most equipment-value migration comes from the advanced, spectral, and photon-counting tiers.
• 2. Photon-counting CT changes the premium market before it changes the installed base. Early adoption is concentrated in academic centers, flagship hospitals, and advanced cardiovascular and oncology programs. Its near-term effect is a premium value-mix shift and new reference-site competition, while spectral and wide-detector systems remain the main premium-replacement path for most hospitals.
• 3. Service and aftermarket remain strategic control points. Service contracts, tubes, parts, and software upgrades support recurring revenue, account retention, and replacement planning. OEMs, independent service organizations, and component suppliers all compete for these installed-base economics.
• 4. China is a separate competitive system. Domestic substitution, tender reform, premium localization, and the gap between headline tender savings and realized OEM pricing require China to be analyzed on its own terms.
• 5. AI monetization depends on workflow and payment architecture. There is no single CT AI adoption curve. Cardiac CT AI is reimbursement-linked, stroke AI is established but maturing, lung AI depends on screening-program execution, and reconstruction AI is often captured inside scanner or upgrade pricing.
• 6. Buyer power is consolidating. Large IDNs, academic health systems, and outpatient imaging networks gain purchasing share, which raises the weight of fleet standardization, upgrade rights, uptime commitments, and enterprise AI governance in vendor selection.
• 7. Financing is becoming part of product strategy. Leasing, managed-equipment, and public-private structures increasingly decide whether demand converts into placements, particularly in capacity-expansion markets.

Competitive Structure

Marketstrat organizes the CT market into nine strategic clusters to show where value is controlled and how each group of competitors monetizes its position: premium integrated OEMs; China and value-tier challengers; photon-counting and advanced spectral CT; cardiac CT AI; stroke and neuro CT AI; lung, thoracic, and multi-condition CT AI; enterprise AI orchestration and workflow; service, aftermarket, and enabling components; and financing and managed equipment.

Within each cluster, the report assesses where the moat sits, how revenue is captured, relative competitive standing, evidence and regulatory position, geographic reach, installed-base and channel strength, principal execution risks, and signals to monitor over the next 12 to 24 months.

Companies covered include Siemens Healthineers, GE HealthCare, Canon Medical Systems, Philips, Fujifilm Healthcare / Hitachi legacy CT, United Imaging Healthcare, Neusoft Medical Systems, Wandong Medical, MinFound Medical Systems, HeartFlow, Cleerly, Elucid, Caristo Diagnostics, Artrya, Circle Cardiovascular Imaging, Keya Medical, Riverain Technologies, Bunkerhill Health, Viz.ai, RapidAI, Aidoc, Brainomix, Nicolab, Optellum, Coreline Soft, DeepHealth, Aidence, Gleamer, Infervision, deepc, Microsoft / Nuance, Sectra, Sirona Medical, Visage Imaging / Pro Medicus, Blackford / Calantic, Varex Imaging, Dunlee, TRIMEDX, Agiliti, Block Imaging, Siemens Financial Services, GE HealthCare Financial Services, and Philips Capital.

What's Inside

Core global market model, 2024A–2035E. CT procedures, active installed base, replacement and expansion shipments, systems revenue, service contracts, replacement tubes and parts, software upgrades, vendor-net CT AI, and enterprise AI orchestration, plus an extended value pool that adds CT-attributable contrast media and mobile CT service.

Scanner segmentation. T1 Basic / Entry CT, T2 Mainstream / Mid-Range CT, T3 Advanced Wide-Detector / High-End CT, T4 Spectral / Dual-Energy CT, and T5 Photon-Counting CT.

Clinical market structure. Neurology / stroke, cardiac / coronary CT, lung screening, oncology staging and surveillance, trauma / emergency, abdominal / pelvic, vascular / pulmonary embolism CTA, pediatric, CT-guided intervention / biopsy, and CT colonography / GI screening.

End-use market structure. Large IDNs and academic health systems, regional and community hospital systems, standalone and critical-access hospitals, outpatient imaging centers and radiology groups, and government, public-sector, military, and national health systems, with a care-setting overlay.

Strategic frameworks. The Markintel® framework stack, including the M³ Market Momentum Matrix, M-TEM, T-DIC, Solution Adoption & Growth Matrix, ARC-Index, CT Upgrade & Package Ladder, GTM Growth Maturity Matrix, and a Competitive Control-Plane Scorecard.

Scenarios and priorities. Base, Bull, and Bear cases, scenario drivers, leading indicators, a risk and opportunity matrix, and strategic priorities for OEMs, AI vendors, service providers, healthcare providers, and investors.

Geographic coverage. North America, Europe, APAC, Latin America, and the Middle East and Africa, with country-level analysis of the United States, Canada, Germany, the United Kingdom, France, Italy, Spain, China, Japan, India, Brazil, Mexico, Saudi Arabia / UAE, and South Africa.

Who Should Read This Report

• CT and medical imaging OEM executives, product management, and portfolio leaders
• Corporate strategy and corporate development teams
• Service and aftermarket organizations; X-ray tube, detector, and component suppliers
• Clinical AI and imaging-software vendors; enterprise imaging, PACS, reporting, and orchestration platforms
• Healthcare investors, banks, and private equity
• IDN, hospital, and outpatient imaging leaders, including procurement and imaging-operations teams
• Financing, leasing, and managed-equipment providers
• Consulting and advisory firms, and government and public-sector imaging programs

Why This Report

The CT market is too complex for a shipment-only forecast and too operational for a generic top-down estimate. Marketstrat® sits between sell-side research and traditional syndicated market reports: structured enough for strategy, corporate development, investment, and consulting teams, and close enough to product architecture, clinical workflow, reimbursement, tenders, and installed-base economics to be useful to operators.

Use the report to test market-entry assumptions, refine product roadmaps, prioritize countries and buyer segments, benchmark competitors, time premium-technology investments, model service and AI attach rates, assess partnerships or acquisitions, build investment theses, structure financing offers, or challenge an existing CT forecast.

Report Details

• Title: Global CT Scanners Market Horizon Report
• Subtitle: Market Structure, Forecasts, Clinical Demand, Competitive Dynamics, and AI Monetization Architecture, 2024A–2035E
• Type: Marketstrat® Horizon Report (flagship, in-depth)
• Report ID: MINTH-02101
• Publication: July 2026
• Forecast Period: 2024A–2035E
• Length: 237 pages
• Content: 100 tables and 50 figures, including proprietary strategic frameworks
• Format: PDF digital delivery
• Geographic Coverage: North America | Europe | APAC | Latin America | Middle East and Africa
• Country Coverage: United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India, Brazil, Mexico, Saudi Arabia / UAE, and South Africa
• License Options: Individual ($4,950), Team ($5,450), Enterprise ($8,950)

Table of Contents

SECTION 1: EXECUTIVE SUMMARY

• 1.1 GLOBAL CT MARKET OUTLOOK
• 1.2 CORE MARKET THESIS
• 1.3 MARKET VALUE MIGRATION
• 1.4 CLINICAL AND BUYER STRUCTURE
• 1.5 STRATEGIC FRAMEWORK SYNTHESIS
• 1.6 REGIONAL MARKET OUTLOOK
• 1.7 TECHNOLOGY AND AI OUTLOOK
• 1.8 COMPETITIVE OUTLOOK
• 1.9 SCENARIO OUTLOOK
• 1.10 STRATEGIC PRIORITIES
• 1.11 SIGNALS TO WATCH
• 1.12 EXECUTIVE CONCLUSION

SECTION 2: RESEARCH SCOPE, DEFINITIONS, AND METHODOLOGY

• 2.1 SCOPE OF THE REPORT
• 2.2 MARKET DENOMINATOR ARCHITECTURE
• 2.3 CT SCANNER TIER TAXONOMY
• 2.4 REVENUE LAYER DEFINITIONS
• 2.5 AI REVENUE CONVENTION
• 2.6 GEOGRAPHIC COVERAGE
• 2.7 FORECAST METHODOLOGY
• 2.8 CLINICAL-SEGMENT ALLOCATION METHODOLOGY
• 2.9 END-USE ORGANIZATION AND CARE-SETTING METHODOLOGY
• 2.10 SOURCE METHODOLOGY
• 2.11 EVIDENCE CONFIDENCE FRAMEWORK
• 2.12 SCENARIO METHODOLOGY
• 2.13 METHODOLOGY IMPLICATIONS FOR READING THE FORECAST

SECTION 3: WORLD MARKET STRUCTURE AND STRATEGIC FRAMEWORKS

• 3.1 GLOBAL CT MARKET SIZE AND GROWTH
• 3.2 SYSTEMS REVENUE VERSUS LIFECYCLE REVENUE
• 3.3 REGIONAL MARKET STRUCTURE
• 3.4 CORE CT ECOSYSTEM REVENUE BY LAYER
• 3.5 INSTALLED BASE, PROCEDURE DEMAND, AND SHIPMENT LOGIC
• 3.6 REVENUE GROWTH DECOMPOSITION
• 3.7 CT MARKET STRUCTURE BY CLINICAL SEGMENT
  • Clinical Demand Structure
  • Systems Revenue by Primary Clinical Demand Driver
  • Clinical-Segment Value Intensity
  • Clinical-Segment Strategic Implications
• 3.8 CT MARKET STRUCTURE BY END-USE ORGANIZATION AND CARE SETTING
  • Buyer Structure
  • Technology and Monetization by Buyer Type
  • Care-Setting Overlay
  • End-Use Strategic Implications
• 3.9 STRATEGIC IMPLICATIONS OF MARKET STRUCTURE
• 3.10 STRATEGIC FRAMEWORK ARCHITECTURE
• 3.11 M³ MARKET MOMENTUM MATRIX: CT REVENUE LAYERS
• 3.12 M³ MARKET MOMENTUM MATRIX: CT SCANNER TIERS
• 3.13 M-TEM: CT TECHNOLOGY EVOLUTION MATRIX
• 3.14 T-DIC: TECHNOLOGY DIFFUSION AND IMPACT CURVE
• 3.15 SOLUTION ADOPTION & GROWTH MATRIX: CT AI AND WORKFLOW USE CASES
• 3.16 ARC-INDEX: CT AI COMMERCIALIZATION READINESS
• 3.17 CT UPGRADE & PACKAGE LADDER
• 3.18 STRATEGIC FRAMEWORK SYNTHESIS

SECTION 4: TECHNOLOGY EVOLUTION AND AI MONETIZATION ARCHITECTURE

• 4.1 TECHNOLOGY ROADMAP
• 4.2 PHOTON-COUNTING CT
• 4.3 SPECTRAL, DUAL-ENERGY, AND WIDE-DETECTOR CT
• 4.4 RECONSTRUCTION AND LOW-DOSE AI
• 4.5 CT AI MONETIZATION STACK
• 4.6 CCTA AI AND CORONARY PLAQUE ANALYSIS
• 4.7 VENDOR-NET CT AI REVENUE FORECAST
• 4.8 STROKE AND NEURO CT AI
• 4.9 LUNG SCREENING AND PULMONARY NODULE AI
• 4.10 ONCOLOGY, INCIDENTAL FINDINGS, AND MULTI-CONDITION CT AI
• 4.11 ENTERPRISE AI ORCHESTRATION
• 4.12 AI MONETIZATION ARCHITECTURE
• 4.13 STRATEGIC IMPLICATIONS

SECTION 5: COMPETITIVE LANDSCAPE AND STRATEGIC CLUSTERS

• 5.1 COMPETITIVE LANDSCAPE OVERVIEW
• 5.2 GLOBAL CT OEM SHARE BANDS
• 5.3 GTM GROWTH MATURITY MATRIX
• 5.4 PREMIUM INTEGRATED OEMS
  • COMPANY SPOTLIGHTS: PREMIUM INTEGRATED OEMS
    • Siemens Healthineers
    • GE HealthCare
    • Canon Medical Systems
    • Philips
    • Fujifilm Healthcare / Hitachi Legacy CT
    • Premium Integrated OEM Cluster Outlook
• 5.5 CHINA AND VALUE-TIER OEM CHALLENGERS
  • COMPANY SPOTLIGHTS: CHINA AND VALUE-TIER OEM CHALLENGERS
    • United Imaging Healthcare
    • Neusoft Medical Systems
    • Wandong Medical
    • China and Value-Tier OEM Cluster Outlook
• 5.6 PHOTON-COUNTING CT COMPETITIVE RACE
  • COMPANY SPOTLIGHTS: PHOTON-COUNTING AND ADVANCED SPECTRAL CT
    • Siemens Healthineers
    • GE HealthCare
    • Canon Medical
    • Philips
    • United Imaging Healthcare
    • Neusoft Medical Systems
    • Photon-Counting and Advanced Spectral CT Cluster Outlook
• 5.7 CT AI VENDOR CLUSTERS
  • COMPANY SPOTLIGHTS: CARDIAC CT AI
    • HeartFlow
    • Cleerly
    • Elucid
    • Caristo Diagnostics
    • Artrya
    • Other Notable Cardiac CT AI Competitors
    • Cardiac CT AI Cluster Outlook
  • COMPANY SPOTLIGHTS: STROKE AND NEURO CT AI
    • Viz.ai
    • RapidAI
    • Aidoc
    • Brainomix
    • Nicolab
    • Stroke and Neuro CT AI Cluster Outlook
  • COMPANY SPOTLIGHTS: LUNG SCREENING AND THORACIC CT AI
    • Optellum
    • Coreline Soft
    • DeepHealth, Including Aidence and Gleamer
    • Riverain Technologies
    • Infervision
    • Oncology, Incidental Findings, and Multi-Condition CT AI
    • Aidoc: Multi-Condition Detection and Patient Management
    • DeepHealth and Gleamer: Cancer Detection and Reporting Across Modalities
    • Coreline Soft: Multi-Disease Screening and Radiotherapy Segmentation
    • Infervision: Imaging AI Across Diagnosis, Treatment, and Follow-Up
    • Lung, Oncology, and Multi-Condition CT AI Cluster Outlook
• 5.8 ENTERPRISE ORCHESTRATION AND PLATFORM COMPETITION
  • COMPANY SPOTLIGHTS: ENTERPRISE AI ORCHESTRATION AND WORKFLOW
    • Aidoc
    • deepc
    • Microsoft / Nuance
    • Sectra
    • Sirona Medical
    • Visage Imaging / Pro Medicus
    • Other Notable Platforms and Strategic Watchlist
    • Blackford Analysis / Calantic: Historical Platform Case Study
    • Other Notable Platforms
    • Enterprise AI Orchestration and Workflow Cluster Outlook
• 5.9 SERVICE AND AFTERMARKET COMPETITIVE STRUCTURE
  • COMPANY SPOTLIGHTS: OEM LIFECYCLE SERVICES
    • Siemens Healthineers Customer Services
    • GE HealthCare Services
    • Canon Medical Customer Service
    • Philips Healthcare Services
    • United Imaging Customer Service
    • COMPANY SPOTLIGHTS: ENABLING COMPONENTS
    • Varex Imaging
    • Dunlee
  • COMPANY SPOTLIGHTS: INDEPENDENT SERVICE, ASSET MANAGEMENT, AND REFURBISHMENT
    • TRIMEDX
    • Agiliti
    • Block Imaging
    • Other Notable Independent Participants
    • Service, Aftermarket, and Enabling Components Cluster Outlook
• 5.10 FINANCING AND MANAGED EQUIPMENT ENABLEMENT
  • Siemens Financial Services and Siemens Healthineers Value Partnerships
  • GE HealthCare Financial Services
  • Philips Capital and Managed Services
  • Financing and Managed-Equipment Structures
  • Financing and Managed Equipment Cluster Outlook
• 5.11 COMPETITIVE CONTROL-PLANE SCORECARD
• 5.12 COMPANY AND CLUSTER IMPLICATIONS
• 5.13 COMPETITIVE OUTLOOK THROUGH 2035

SECTION 6: REGIONAL AND COUNTRY MARKET ANALYSIS

• 6.1 REGIONAL MARKET OVERVIEW
• 6.2 REGIONAL DEMAND, INSTALLED BASE, AND LIFECYCLE ECONOMICS
• 6.3 NORTH AMERICA
• 6.4 UNITED STATES
• 6.5 EUROPE
• 6.6 GERMANY
• 6.7 UNITED KINGDOM
• 6.8 FRANCE, ITALY, AND SPAIN
• 6.9 APAC
• 6.10 CHINA
• 6.11 JAPAN
• 6.12 INDIA
• 6.13 REST OF APAC
• 6.14 LATIN AMERICA
• 6.15 BRAZIL
• 6.16 MEXICO
• 6.17 MIDDLE EAST AND AFRICA
• 6.18 SAUDI ARABIA AND UAE
• 6.19 SOUTH AFRICA AND REST OF MEA
• 6.20 COUNTRY ARCHETYPES
• 6.21 REGIONAL STRATEGIC IMPLICATIONS

SECTION 7: SCENARIO OUTLOOK AND STRATEGIC PRIORITIES

• 7.1 SCENARIO FRAMEWORK
• 7.2 BASE CASE
• 7.3 BULL CASE
• 7.4 BEAR CASE
• 7.5 SCENARIO SENSITIVITY BY REVENUE LAYER
• 7.6 SCENARIO DRIVERS
• 7.7 CLINICAL-SEGMENT AND END-USE EXPOSURE TO THE SCENARIO RANGE
• 7.8 LEADING INDICATORS
• 7.9 STRATEGIC PRIORITIES FOR CT OEMS
• 7.10 STRATEGIC PRIORITIES FOR AI VENDORS AND ORCHESTRATION PLATFORMS
• 7.11 STRATEGIC PRIORITIES FOR SERVICE AND AFTERMARKET PROVIDERS
• 7.12 STRATEGIC PRIORITIES FOR HEALTHCARE PROVIDERS
• 7.13 STRATEGIC PRIORITIES FOR INVESTORS
• 7.14 RISK AND OPPORTUNITY MATRIX
• 7.15 STRATEGIC OUTLOOK